Publications, Abstracts & Patents

Publications

Norton SD, Schlievert PM, Novick R, and Jenkins MK. Molecular requirements for T cell activation by staphylococcal toxic shock syndrome toxin-1. J Immunol 1990; 144:2089.
Jenkins MK, Mueller D, Schwartz RH, Carding S, Bottomly K, Stadecker MJ, Urdahl KB, and Norton SD. Induction and maintenance of anergy in mature T cells. In Gupta P, Paul W, Cooper M, Rothenberg E, editors. Mechanisms of lymphocyte activation and immune regulation III: Development Biology of Lymphocytes. New York: Plenum Press; 1991: 167-176.
Norton SD, Hovinen DE, and Jenkins MK. IL-2 secretion and T cell clonal anergy are induced by distinct biochemical pathways. J Immunol 1991; 146:1125.
Jenkins MK, Taylor PS, Norton SD, and Urdahl KB. CD28 delivers a costimulatory signal important for antigen-specific IL-2 production by human T cells. J Immunol 1991; 147:2461.
Urdahl KB, Jenkins MK and Norton SD. Accessory cell-derived costimulatory signals regulate T cell proliferation. Ann N Y Acad Sci 1991; 636:33.
Jenkins MK and Norton SD. T Lymphocyte clonal expansion. In: Roitt IM, Delves PJ, editors. Encyclopedia of Immunology Vol III. London: Academic Press; 1992: 1467-1556.
Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, and Jenkins MK. CD28’s ligand, B7, provides a costimulatory signal to alloreactive T cells. J Immunol 1992; 149:1556.
Jenkins MK, DeSilva DR, Johnson JG, and Norton SD. Costimulatory factors and signals relevant for antigen presenting cell function. Adv Exp Med Biol 1993; 329:87.
Spencer NFL, Norton SD, Harrison LL, Li G, and Daynes RA. Altered regulation of interleukin-10 production with normal aging: Possible linkage to the age-associated decline in dehydroepiandrosterone (DHEA) and its sulfated derivative. Expt Gerontol 1996; 31(3):393.
Norton SD, Harrison LL, Yowell R, and Araneo BA. Administration of dehydroepiandrosterone sulfate (DHEAS) retards onset but not progression of autoimmune disease in NZB/W mice. Autoimmunity 1997; 26:161.

Abstracts

Norton SD, Schlievert PM, Novick RP, and Jenkins MK. Molecular requirements for T cell activation by the staphylococcal toxic shock syndrome toxin-1. Autumn Immunol Conf; St. Louis, MO. 1989 18:71.
Norton SD, Takei F, and Jenkins MK. Role of LFA-1/ICAM-1 interactions in the costimulatory pathway of T cell activation. FASEB; New Orleans, LA. 1990 FASEB Journal 4:A2203.
Norton SD, Hovinen DE, and Jenkins MK. IL-2 secretion and T cell clonal anergy are induced by distinct biochemical pathways. Autumn Immunol Conf; Chicago, IL. 1990 19:42.
Norton SD, Hovinen DE, and Jenkins MK. IL-2 secretion and T cell clonal anergy are induced by distinct biochemical pathways. FASEB; Atlanta, GA. 1991 FASEB Journal 5:A1376.
Norton SD, Urdahl KB, Zuckerman L, Shefner R, Miller J, and Jenkins MK. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. Autumn Immunol Conf; Chicago, IL. 1991 20:25.
Norton SD, Urdahl KB, Zuckerman L, Shefner R, Miller J, and Jenkins MK. CD28’s ligand, B7, provides a costimulatory signal to alloreactive T cells. FASEB; Anaheim, CA. 1992 FASEB Journal 6:A1662.
Norton SD and Miller J. Transcription factors that regulate the interleukin-2 gene during the restimulation of anergic T cells. Keystone symposia on molecular and cellular biology; Keystone, CO. 1993 J Cell Bio 17a:B960.
Araneo BA, Kreisel J, Ricigliano J, and Norton SD. Vitamin D3-enhanced protection in two murine models of viral infection: Influenza A and herpes simplex 2. 8th International congress of mucosal immunology; San Diego, CA. 1995.
Spencer NFL, Norton SD, and Daynes RA. Redox regulation of cytokine production: IL-10 is enhanced under pro-oxidant and inhibited under anti-oxidant conditions. 9th International congress of Immunology; San Francisco, CA. 1995.
Araneo BA, Norton SD, Lockerbie RO, Dowell C, Dowell T, Lohman R, and Siemionow M. The desensitization of PMN inflammatory responses by DHEA. Meeting on anti-cortisols; Las Vegas, NV. 1997.
Chawla S, Chua V, Wong S, Quon D, Moradkhani A, Wang K, Bhuiyan I, Pelenghian O, Scott S, Krykan N, Zhang K, Norton S, Wu K, Kim T, Gordon E. Updated Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer. Connective Tissue Oncology Society Annual Meeting; Virtual. 2020

Patents

Screening for DHEA mimetics using members of the inflammatory cell signaling cascade specifically modulated by DHEA as targets. Patent date: Issued Sep 16, 1999; Patent issuer and number: us WO 1999045930 A1
Method for reducing mast cell mediated allergic reactions. Patent date: Issued May 19, 1998; Patent issuer and number: us US5859000 A